The research was published on Chemical Biology & Drug Design. The MYC protein is a well-established driver in up to 70% of human cancers, but has long been considered “undruggable” due to the ...

MYC is dysregulated in nearly 70% of human cancers, where it influences a vast network of biological processes including cell cycle control, metabolism, apoptosis, angiogenesis, and immune evasion.

Pioneered by Dr. Chidiebere Awah MD, PhD, our CEO and Principal Investigator, UTRxM1-18 targets oncogenic c-MYC by recognizing specific motifs and switching the ribosome machinery from a ...

Inhibiting RMB42 disrupted production of Myc proteins in pancreatic cancer cells. This approach could curtail the growth of several cancer types. A review paper published last year in European ...

Over the past 21 months, the Company has raised $86 million to support the completion of its randomized, multicenter, double-blind, placebo-controlled Phase 2b trial of IGV-001 in patients with ...

Study: MYC-Targeting Inhibitors Generated from a Stereodiversified Bicyclic Peptide Library. Image Credit: Christoph Burgstedt / Shutterstock.com MYC, a transcription factor involved in most human ...

MRT-2359 is an investigational, orally bioavailable, GSPT1-directed MGD discovered by Monte Rosa Therapeutics. Cancers driven by MYC overexpression have been demonstrated to be dependent on GSPT1, ...

Below is Validea's ETF fundamental report for iShares Goldman Sachs Software Index Fund ETF (IGV). The report looks at IGV's exposure to the major investing factors including value, quality ...

The trial is a randomized, multicenter, double-blind, placebo-controlled Phase 2b study (NCT04485949) designed to assess the safety and efficacy of IGV-001, an autologous biologic-device ...